M. T. Pagliari

发表

Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study

F. Rosendaal, P. Mannucci, A. Tosetto, 2022, Journal of thrombosis and haemostasis : JTH.

The ADAMTS13‐von Willebrand factor axis in COVID‐19 patients

G. Grasselli, F. Blasi, F. Peyvandi, 2020, Journal of Thrombosis and Haemostasis.

Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease

P. Bucciarelli, F. Peyvandi, L. Baronciani, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis.

F. Rosendaal, I. Martinelli, P. Bucciarelli, 2020, Thrombosis research.

Interferon-β but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: A clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs

A. Oliviero, M. Rotondi, L. Chiovato, 2011, Journal of Neuroimmunology.

Recreational opium use as a risk factor for coronary artery disease: results from the premature coronary artery disease Milano-Iran (MIran) study

F. Rosendaal, S. Abbasi, S. Sadeghian, 2020 .

Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis

F. Rosendaal, I. Martinelli, S. Passamonti, 2016, PloS one.

Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination

P. Bucciarelli, F. Peyvandi, L. Baronciani, 2015, Journal of thrombosis and haemostasis : JTH.

The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients

C. Cordiglieri, F. Peyvandi, L. Baronciani, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura

F. Peyvandi, M. T. Pagliari, I. Mancini, 2019, Journal of thrombosis and haemostasis : JTH.

The ISTH Bleeding Assessment Tool and the risk of future bleeding

F. Rosendaal, M. M. Gorski, M. Abbattista, 2018, Journal of thrombosis and haemostasis : JTH.

Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels

F. Rosendaal, P. Bucciarelli, F. Peyvandi, 2015, Journal of thrombosis and haemostasis : JTH.

Factor V Leiden but not the factor II 20210G>A mutation is a risk factor for premature coronary artery disease: a case-control study in Iran

F. Rosendaal, S. Abbasi, S. Sadeghian, 2023, Research and practice in thrombosis and haemostasis.

von Willebrand disease type 1 mutation p.Arg1379Cys and the variant p.Ala1377Val synergistically determine a 2M phenotype in four Italian patients

F. Peyvandi, L. Baronciani, M. T. Pagliari, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura

Luigi Cavallo, Flora Peyvandi, Safwat Abdel-Azeim, 2016, Thrombosis and Haemostasis.

The type 2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress

M. Papi, M. Spirito, A. Arcovito, 2013, Journal of thrombosis and haemostasis : JTH.

Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation

F. Peyvandi, L. Baronciani, M. T. Pagliari, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis

F. Rosendaal, I. Martinelli, P. Bucciarelli, 2021, PloS one.

Opium as a risk factor for early-onset coronary artery disease: Results from the Milano-Iran (MIran) study

F. Rosendaal, S. Abbasi, S. Sadeghian, 2023, PloS one.

A synonymous (c.3390C>T) or a splice‐site (c.3380‐2A>G) mutation causes exon 26 skipping in four patients with von Willebrand disease (2A/IIE)

F. Peyvandi, L. Baronciani, M. T. Pagliari, 2013, Journal of thrombosis and haemostasis : JTH.

A comparative study in patients with type 2 von Willebrand disease using 4 different platelet-dependent von Willebrand factor assays

F. Peyvandi, L. Baronciani, M. T. Pagliari, 2023, Research and practice in thrombosis and haemostasis.

Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination

P. Bucciarelli, L. Baronciani, M. T. Pagliari, 2015, Journal of thrombosis and haemostasis : JTH.

A synonymous (c.3390C>T) or a splice‐site (c.3380‐2A>G) mutation causes exon 26 skipping in four patients with von Willebrand disease (2A/IIE)

L. Baronciani, M. T. Pagliari, M. Canciani, 2013, Journal of thrombosis and haemostasis : JTH.

Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2

F. Peyvandi, L. Baronciani, M. T. Pagliari, 2022, Blood advances.